CDH arises from incomplete diaphragm formation during fetal development, permitting abdominal organs to occupy the thoracic space and impair lung development, as described in the packet definition. No causative gene variants or hereditary inheritance patterns are captured in the gene-level or inheritance data fields of this packet.

CDH is defined by the structural presence of a posterolateral diaphragmatic defect. Five subtypes are categorized in this packet, including anterior diaphragmatic hernia and forms with associated cardiovascular defects, reflecting recognized anatomical and syndromic variation. No molecular diagnostic criteria or genetic testing protocol fields are populated in this packet.

No FDA-approved systemic drug therapies or foundational therapies are documented in this packet for CDH. Clinical trials documented in the packet include a Phase 4 study examining inhaled nitric oxide in CDH (NCT05213676, recruiting) and a pilot trial of fetoscopic endoluminal tracheal occlusion for fetal CDH (NCT07767825). These represent investigational approaches captured in the trial dataset of this packet.

The packet definition identifies high mortality as a characteristic outcome associated with CDH. Natural history data fields beyond the definition are not populated in this packet. Subtype documentation, including a cardiovascular-defect variant, indicates that clinical severity varies across subtype categories as captured in this packet.

Ten clinical trials are documented in this packet, covering medical devices, procedural interventions, drug therapy, and other approaches, with an academic sponsor profile. The Kisho literature tracker documents 428 classified publications related to CDH, with epidemiology and natural history as the dominant research category. The literature base includes 92 reviews and 74 case reports, alongside biomarker research and recent trial publications. Gene therapy publications are present in the broader literature base as tracked in this packet.